Zenas BioPharma (ZBIO) news

Recent news

Zenas Biopharma announces inducement grants under Nasdaq listing rule 5635(c)(4)

AInvest Wire · Jun 17, 2026

Zenas Biopharma - Phase 3 Indigo trial of obexelimab meets primary and all key secondary endpoints

Zenas BioPharma (Nasdaq: ZBIO) announced that the Phase 3 INDIGO trial of obexelimab in patients with Immunoglobulin G4-Related Disease (IgG4-RD) met its primary endpoint and all four key secondary endpoints. The trial, which enrolled 200 patients across multiple centers globally, demonstrated a…

AInvest Wire · Jun 2, 2026

Zenas BioPharma raises $225 mln in US IPO

AInvest Wire · Sep 13, 2024

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by